Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung Cancer [ELCC 2021 Virtual Press Release]

Source : https://www.esmo.org/newsroom/press-office/second-drug-targeting-kras-g12c-shows-benefit-in-mutated-non-small-cell-lung-cancer

LUGANO, Switzerland; DENVER, CO, USA - Clinical activity with a second drug inhibiting KRAS G12C confirms its role as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC) harbouring this mutation, according to results from a study with the KRAS G12C inhibitor adagrasib reported at the European Lung Cancer Virtual Congress 2021.